Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Menéndez, M. Cavalcanti, S. Reyes, I. Aldabó, J. Mensa, R. Martinez, X. Filella, A. Torres (Valencia, Barcelona, Spain). Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia. Eur Respir J 2006; 28: Suppl. 50, 4653

Member's Comments

No comment yet.

Related content which might interest you: C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Management-based risk prediction in community-acquired pneumonia by scores and biomarkers Source: Eur Respir J 2013; 41: 974-984 Year: 2013 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study Source: Eur Respir J 2009; 34: 1364-1375 Year: 2009 Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia Source: Eur Respir J 2008; 32: 726-732 Year: 2008 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Biomarkers in severe community-acquired pneumonia (SCAP) prognosis, complications and outcomes Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Procalcitonin as etiological marker of severe community-acquired pneumonia Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 The comparison of diagnostic relevance of protein C, C-reactive protein and endothelin-1 for prediction of lung vessel thrombosis in patients with community-acquired pneumonia Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019 Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia Source: Eur Respir J 2007; 30: 517-524 Year: 2007 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007